Hite Christopher 4
4 · Royalty Pharma plc · Filed Mar 25, 2021
Insider Transaction Report
Form 4
Hite Christopher
EVP & Vice Chairman
Transactions
- Sale
LP interests in RPI US Partners 2019, LP
2021-03-23$469.86/sh−31,959$15,016,224→ 30,541 totalExercise: $0.00→ Class A Ordinary Shares (319,590 underlying)
Footnotes (2)
- [F1]Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.
- [F2]These RPI US LP Interests were withheld to cover tax withholding obligations.